Board summary
Key figures
54,699
Registered population
58.5% aged 18–64
23.2%
Aged 65+
ICB 20.0% · England 17.9%
2.4%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
13.5%
In IMD quintile 1
ICB 30.6% · England 21.0%
~7,524
Core20 residents (est.)
Resident basis; registered basis ~7,669 · see page 3
10,883
Hypertension register
+7.28% in 3 yrs · England +5.60%
651
SMI register
47.7% of Chorley's
1,496
COPD register
Reviews +5.02% in 3 yrs
Forecast to 2030
12,700
Hypertension patients, 2030
+1,817 on today
70.5%
QRISK ≥20% on statins, 2030
+4.47pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid and statin treatment lags England.
Lipid therapy for QRISK ≥ 20% (60.4% vs England 63.6%) and diabetes statins (70.3% vs 73.2%) trail nationally, which may reflect unverified recall gaps.
Unreviewed asthma cohort alongside high child prescribing.
Despite 69.7% annual review uptake (England 65.7%), about 1,300 asthma patients lack reviews while child prescribing is 2,037 per 1,000 (England 1,488).
Hypertension control and SMI checks exceed England.
SMI blood pressure checks rose +9.9 pp over three years to 83.6% (England 83.4%), while hypertension treatment to target reaches 71.6% (England 70.3%).
Population, age and ethnicity
With 23.2% aged 65+, the PCN has an older population than England's 17.9%
Chorley Central PCN has 54,699 registered patients with an older demographic: 23.2% (12,687) are aged 65+, compared to 20.2% in Chorley, 20.0% in NHS Lancashire and South Cumbria ICB, and 17.9% in England. Adults aged 18–64 account for 58.5% and children aged 0–17 for 18.3%. Census estimates show 97.7% White residents (Chorley 95.6%, ICB 87.8%, England 81.1%) and 2.4% ethnic minorities, reflecting resident areas rather than registrations. Older age profiles may increase frailty demand ahead of projected 1.8% list growth to 2030, which uses an unverified methodology.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Chorley local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Chorley LA) | 1,635 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Chorley LA) | 743 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Chorley LA) | 10.4 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 13.5% across the PCN and concentrated entirely within three practices
The PCN Core20 cohort is 13.5% (Chorley 11.4%, England 21.0%, ICB 30.6%). Deprivation is concentrated in The Chorley Surgery (24.9%, est. 2,455 patients), Library House Surgery (21.9%, est. 3,625 patients) and Regent House Surgery (20.8%, est. 1,589 patients), whereas Coppull Medical Practice, Granville House Med Ctre and The Euxton Medical Centre record 0.0%. A reconciliation warning notes the weighted practice share of 14.0% exceeds the PCN rate by 0.52 percentage points. Focusing outreach on high-volume practices targets resources where deprivation is concentrated.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
651
SMI register
1.18% recorded prevalence
385
Learning disability register
0.70% recorded prevalence
16
Care homes, 681 beds
In the PCN catchment
9.3%
Provide unpaid care
Chorley, Census 2021
The PCN records 651 severe mental illness patients (1.2% vs Chorley 1.1%, ICB 1.2%, England 1.0%) and 385 learning disability patients (0.7% vs 0.6% across comparators), representing 47.7% and 46.7% of borough registers. Catchment assets include 16 care homes with 681 beds. These inclusion registers and care home beds indicate substantial ongoing care coordination workload across the network.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.2%. Annual BP checks reached 83.6% (England 83.4%) and BMI recording 83.2% (England 82.1%). Smoking cessation offers fell 3.0 pp over three years (England +0.1 pp) to 94.0%, which could reflect unverified referral gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,883
Hypertension register
+7.28%
Register growth, 3 yrs
Chorley +6.44% · England +5.60%
+4.33pp
BP control, under 80
≤140/90 · +4.30pp aged 80+
+1,817
More patients by 2030
Forecast 12,700 (22.70%)
Hypertension case-finding and control
Recorded hypertension prevalence is 19.7% (10,883 patients), above Chorley (17.5%), the ICB (17.2%) and England (15.2%), consistent with an older population (23.2% aged 65+). Prevalence changed +1.3 pp over three years (England +0.8 pp). Recent blood pressure monitoring reached 89.7% (England 90.0%), and patients treated to target reached 71.6% (England 70.3%). For patients aged 80 and over, control is 81.2%, in line with England (81.2%) but below Chorley (82.0%) and the ICB (81.8%). Lower control in patients aged 80 and over compared to local benchmarks indicates an opportunity to review titration protocols.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 60.4%, trailing England (63.6%) and the ICB (61.4%). Statin coverage in diabetes patients aged 40+ without cardiovascular disease is 70.3% (England 73.2%). Lower uptake may reflect unverified recall gaps that practice audits would test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 111,605 | £1.80 | £1.64 | £1.86 | £200,889 |
| Cardiovascular (all), 2025 | 168,974 | £4.05 | £3.38 | £3.33 | £684,345 |
In 2026, lipid-regulating drugs averaged £1.80 per item across 111,605 items (England £1.86, ICB £1.64). Across these items, the PCN spent £6,696 less than at England's unit cost, and £17,857 more than at NHS Lancashire and South Cumbria Integrated Care Board's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.49%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.09%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.2% (4,284 patients; England 6.6%). Annual reviews reached 69.7% (England 65.7%), leaving about 1,300 patients unreviewed. Paediatric asthma prescribing reached 2,037 items per 1,000 aged 5-19, above England (1,488) and the ICB (1,828). Second-hand smoke recording for ages 6-19 is 79.1% (Chorley 82.8%). COPD prevalence is 2.7% (1,496 patients; England 1.9%), with reviews at 81.5% (England 76.4%). Higher paediatric prescribing alongside unreviewed patients could reflect unverified disease control shortfalls that medication and recall audits would clarify.
Cancer register and children's immunisation
Cancer prevalence is 4.9% (2,700 patients; England 3.8%). In childhood immunisations, 24-month MMR dose 1 reaches 95.4% (England 88.3%). However, age-5 coverage falls below the 95.0% target: MMR dose 1 is 91.7% and dose 2 is 86.4% (below target by 8.6 pp), showing a 5.3 pp same-cohort drop. The 4-in-1 booster also trails at 86.4%. This could reflect unverified pre-school recall drop-off.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage (4,642 of 8,863; known-stage share 74.6% of 11,883) were diagnosed at stage 1 or 2 (England 55.3%), falling 22.6 pp below the 75.0% national ambition by 2028 (ICB data, not PCN performance). Early-stage share fell 1.2 pp from 53.6% in 2013, needing about 2,010 extra early diagnoses annually. Early detection was 86.0% for breast, 44.2% for bowel, and 31.1% for lung. PCN three-year cancer prevalence grew +7.5% (England +9.0%), with The Chorley Surgery at +2.3% and Library House Surgery at +4.3%. ICB staging gaps highlight the importance of reviewing practice referral and coding processes.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data (provider performance, not PCN level), Lancashire Teaching Hospitals NHS Foundation Trust achieved 82.9% on the 28-day faster diagnosis standard (75.0% standard; ICB 78.4%, England 79.3%; Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust 82.8%, East Lancashire Hospitals NHS Trust 81.5%). The 62-day referral to treatment rate was 75.0%, falling 10.0 pp below the 85.0% standard (ICB 73.6%, England 71.2%; Wrightington, Wigan and Leigh 76.8%, East Lancashire 73.2%). Computed Tomography 6-week diagnostic waits reached 15.0% (England 9.9%). These provider-level delays reflect wider system pressure along diagnostic pathways.
| Pathways within standard (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.90 | 82.80 | 81.50 | 78.39 | 79.32 |
| 31-day treatment (96%) | 89.43 | 89.04 | 98.11 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 75.04 | 76.78 | 73.16 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | England |
|---|---|---|---|---|
| MRI | 2.41 | 0.49 | 0.43 | 21.40 |
| CT | 14.97 | 7.78 | 0.15 | 9.92 |
| Echocardiography | 13.85 | 24.37 | 0.00 | 28.48 |
| Colonoscopy | 0.00 | 6.10 | 0.95 | 30.83 |
| Gastroscopy | 0.00 | 12.54 | 1.16 | 29.02 |
| All 15 DM01 tests | 26.65 | 14.36 | 3.25 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). Provisional Community Services Dataset figures for June 2026 indicate that 56.9% of community contacts with Chorley borough residents (72,000 of 126,445 contacts) were with adults aged 65 and over (borough-level data, not PCN level). This activity reflects substantial community care utilisation among older residents across the wider borough.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement ranged from 88.5% at Library House Surgery to 100.0% at Coppull Medical Practice (England 92.5%). In the vaccination and immunisation domain, achievement spanned 56.7 pp, with 43.0% at The Chorley Surgery, 44.3% at Library House Surgery, and 99.7% at Coppull Medical Practice (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Euxton | 90 | 0.0 | 72.8% | 77.8% | 95.6% |
| Granville House | 111 | 0.0 | 57.5% | 74.3% | 90.5% |
| Regent House | 102 | 20.8 | 67.9% | 68.5% | 88.1% |
| Library House | 98 | 21.9 | 49.3% | 68.8% | 81.6% |
| Coppull Medical | 106 | 0.0 | 63.3% | 68.8% | 79.8% |
| Chorley | 106 | 24.9 | 58.4% | 69.2% | 71.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 2.3% over three years while diabetes control rose +10.7%
Between 2023 and 2025, Chorley Central PCN showed gains in physical health checks for severe mental illness: blood pressure recording rose +9.9 pp to 83.6% (England +4.4 pp to 83.4%) and BMI recording rose +9.4 pp to 83.2% (England +5.1 pp). Diabetes non-frail HbA1c control increased +10.7% (England +4.4%). Conversely, heart failure reviews fell 2.3% over three years while England grew +8.7%, despite PCN current achievement reaching 84.5% (England 78.5%). Furthermore, smoking cessation support offers fell 3.0 pp (England +0.1 pp) and learning disability prevalence fell 5.0% (England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
COPD register
Smoking support (SMI)
Cancer register
Diabetes HbA1c control
BP check (SMI)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Chorley | Asset | PCN | Chorley |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (681 beds) | n/a | Schools (catchment) | 61 | n/a |
| Children's centres | 5 | 8 | Places of worship | 53 | 75 |
| Libraries | 4 | 4 | Primary schools (LA maintained) | 22 | 39 |
| Primary academies | 4 | 5 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Across 4,284 asthma patients (8.2% vs England 6.6%), 69.7% had an annual review (England 65.7%), leaving about 1,300 unreviewed, alongside 2,037 items prescribed per 1,000 aged 5-19 (England 1,488). For discussion: practices could run structured asthma recall combining inhaler technique checks and prescribing reviews, prioritising high-deprivation sites. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Lipid and diabetes prevention recall
QRISK ≥ 20% lipid therapy is 60.4% (England 63.6%, ICB 61.4%), diabetes statin therapy (40+ without CVD) is 70.3% (England 73.2%), and non-frail diabetes HbA1c <= 58 mmol/mol is 55.6% (England 57.4%). For discussion: clinical pharmacists could run recall and titration reviews for high-risk CVD and diabetes patients. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Learning disability and smoking offer audit
Over 2023 to 2025, learning disability QOF prevalence fell 5.0% (385 patients, 0.7%; England +5.4%, ICB +5.0%) and smoking cessation offers fell 3.0 pp to 94.0% (England +0.1 pp). For discussion: practices could cross-check learning disability coding and embed routine smoking cessation prompts within annual review templates. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive frailty and anticipatory care (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 preventive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertension blood pressure audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register safety netting audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Lipid and diabetes prevention recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 3 · Learning disability and smoking offer audit (p12) | Learning disability register · Learning disability: QOF prevalence · Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
